{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:17:34Z","timestamp":1776374254372,"version":"3.51.2"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cambridge Biomedical Research Centre"},{"DOI":"10.13039\/100014461","name":"BRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Health and Social Care"},{"name":"British Renal Society and Kidney Care UK Joint Grants Programme","award":["15-004"],"award-info":[{"award-number":["15-004"]}]},{"DOI":"10.13039\/100013793","name":"PKD Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Addenbrooke\u2019s Charitable Trust","award":["24\/15 A"],"award-info":[{"award-number":["24\/15 A"]}]},{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"publisher","award":["TF_009_20161125"],"award-info":[{"award-number":["TF_009_20161125"]}],"id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Vasopressin stimulates cyst growth in autosomal dominant polycystic kidney disease (ADPKD) and is a key therapeutic target. Evaluation of high water intake as an alternative to pharmacological vasopressin blockade is supported by patients. However feasibility, safety and adherence-promoting strategies required to deliver this remain unknown.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>Assess the feasibility of a definitive randomized high water intake trial in ADPKD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this prospective open-label randomized trial, adult ADPKD patients with eGFR \u2265 20 ml\/min\/1.73 m2 were randomized to prescribed high water (HW) intake targeting urine osmolality (UOsm) \u2264270 mOsm\/kg, or ad libitum (AW) intake (UOsm &amp;gt;300 mOsm\/kg). Self-management strategies including home-monitoring of urine-specific gravity (USG) were employed to promote adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We enrolled 42 participants, baseline median eGFR (HW 68.4 [interquartile range (IQR) 35.9\u2013107.2] vs. AW 75.8 [IQR 59.0\u2013111.0 ml\/min\/1.73 m2, P = 0.22) and UOsm (HW 353 [IQR 190\u2013438] vs. AW 350 [IQR 240\u2013452] mOsm\/kg, P = 0.71) were similar between groups. After 8 weeks, 67% in the HW vs. 24% in AW group achieved UOsm \u2264270 mOsm\/kg, P = 0.001. HW group achieved lower UOsm (194 [IQR 190\u2013438] vs. 379 [IQR 235\u2013503] mOsm\/kg, P = 0.01) and higher urine volumes (3155 [IQR 2270\u20134295] vs. 1920 [IQR 1670\u20132960] ml\/day, P = 0.02). Two cases of hyponatraemia occurred in HW group. No acute GFR effects were detected. In total 79% (519\/672) of USG were submitted and 90% (468\/519) were within target. Overall, 17% withdrew during the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>DRINK demonstrated successful recruitment and adherence leading to separation between treatment arms in primary outcomes. These findings suggest a definitive trial assessing the impact of high water on kidney disease progression in ADPKD is feasible.<\/jats:p><\/jats:sec>","DOI":"10.1093\/qjmed\/hcz278","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T11:10:09Z","timestamp":1572001809000},"page":"258-265","source":"Crossref","is-referenced-by-count":22,"title":["High water vs. ad libitum water intake for autosomal dominant polycystic kidney disease: a randomized controlled feasibility trial"],"prefix":"10.1093","volume":"113","author":[{"given":"R","family":"El-Damanawi","sequence":"first","affiliation":[{"name":"Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge"},{"name":"Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Anaesthesia, Department of Medicine, University of Cambridge, Cambridge"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Harris","sequence":"first","affiliation":[{"name":"PKD Charity, 91 Royal College, London"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L B","family":"Cowley","sequence":"first","affiliation":[{"name":"Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge"},{"name":"Patient Led Research Hub, Cambridge NIHR Biomedical Research Centre, Cambridge"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Bond","sequence":"first","affiliation":[{"name":"Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Pavey","sequence":"first","affiliation":[{"name":"Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R N","family":"Sandford","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, University of Cambridge, Hills Road, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I B","family":"Wilkinson","sequence":"first","affiliation":[{"name":"Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge"},{"name":"Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F E","family":"Karet Frankl","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, University of Cambridge, Hills Road, Cambridge, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T F","family":"Hiemstra","sequence":"first","affiliation":[{"name":"Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge"},{"name":"Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"2020040609453023000_hcz278-B1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"2020040609453023000_hcz278-B2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1681\/ASN.2014121192","article-title":"The future of polycystic kidney disease research\u2014as seen by the 12 Kaplan awardees","volume":"26","author":"Antignac","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020040609453023000_hcz278-B3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2020040609453023000_hcz278-B4","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"2020040609453023000_hcz278-B5","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"},{"key":"2020040609453023000_hcz278-B6","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bcp.12136","article-title":"New treatments for autosomal dominant polycystic kidney disease","volume":"76","author":"Chang","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2020040609453023000_hcz278-B7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"2020040609453023000_hcz278-B8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MNH.0b013e3283621510","article-title":"Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease","volume":"22","author":"Devuyst","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2020040609453023000_hcz278-B9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/13543781003588491","article-title":"Novel targets for the treatment of autosomal dominant polycystic kidney disease","volume":"19","author":"Belibi","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"2020040609453023000_hcz278-B10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"2020040609453023000_hcz278-B11","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2020040609453023000_hcz278-B12","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2020040609453023000_hcz278-B13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12645","article-title":"Vasopressin: physiology, assessment and osmosensation","volume":"282","author":"Bankir","year":"2017","journal-title":"J Intern Med"},{"key":"2020040609453023000_hcz278-B14","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A case for water in the treatment of polycystic kidney disease","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020040609453023000_hcz278-B15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000463063","article-title":"Polycystic kidney disease and the vasopressin pathway","volume":"70","author":"van Gastel","year":"2017","journal-title":"Ann Nutr Metab"},{"key":"2020040609453023000_hcz278-B16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.04180609","article-title":"A Pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease","volume":"5","author":"Barash","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020040609453023000_hcz278-B17","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1053\/j.ajkd.2016.07.023","article-title":"Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial","volume":"68","author":"Amro","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2020040609453023000_hcz278-B18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2215\/CJN.03950510","article-title":"Water prescription in autosomal dominant polycystic kidney disease: a pilot study","volume":"6","author":"Wang","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020040609453023000_hcz278-B19","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfu093","article-title":"Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?","volume":"29","author":"Higashihara","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2020040609453023000_hcz278-B20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/cclm-2014-0379","article-title":"Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology","volume":"52","author":"Bolignano","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2020040609453023000_hcz278-B21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ekir.2017.01.006","article-title":"The Effect of renal function and hemodialysis treatment on plasma vasopressin and copeptin levels","volume":"2","author":"Ettema","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2020040609453023000_hcz278-B22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijcard.2016.07.058","article-title":"Elevated copeptin is a prognostic factor for mortality even in patients with renal dysfunction","volume":"221","author":"Engelbertz","year":"2016","journal-title":"Int J Cardiol"},{"key":"2020040609453023000_hcz278-B23","doi-asserted-by":"crossref","first-page":"e0169263","DOI":"10.1371\/journal.pone.0169263","article-title":"Urine concentrating capacity, vasopressin and copeptin in ADPKD and IgA nephropathy patients with renal impairment","volume":"12","author":"Zittema","year":"2017","journal-title":"PLoS One"},{"key":"2020040609453023000_hcz278-B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2017-018794","article-title":"Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD)","volume":"8","author":"Wong","year":"2018","journal-title":"BMJ Open"},{"key":"2020040609453023000_hcz278-B25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.ajkd.2018.11.001","article-title":"Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: a report from the polycystic kidney disease outcomes consortium (PKDOC)","volume":"73","author":"Smith","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2020040609453023000_hcz278-B26","doi-asserted-by":"crossref","first-page":"367.","DOI":"10.1186\/s40900-018-0104-4","article-title":"Inverting the patient involvement paradigm: defining patient led research","volume":"4","author":"Mader","year":"2018","journal-title":"Res Involv Engagem"},{"key":"2020040609453023000_hcz278-B27","first-page":"e022859","article-title":"Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial","volume":"8","author":"El-Damanawi","year":"2018","journal-title":"BMJ Open"},{"key":"2020040609453023000_hcz278-B28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2020040609453023000_hcz278-B29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2020040609453023000_hcz278-B30","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3: 4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2020040609453023000_hcz278-B31","year":"2019"},{"key":"2020040609453023000_hcz278-B32","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1001\/jama.2018.4930","article-title":"Effect of coaching to increase water intake on kidney function decline in adults with chronic kidney disease","volume":"319","author":"Clark","year":"2018","journal-title":"JAMA"},{"key":"2020040609453023000_hcz278-B33","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.ajkd.2014.10.009","article-title":"Modifiable factors associated with copeptin concentration: a general population cohort","volume":"65","author":"van Gastel","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2020040609453023000_hcz278-B34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020040609453023000_hcz278-B35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcz278\/31879512\/hcz278.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/qjmed\/article-pdf\/113\/4\/258\/33015652\/hcz278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/qjmed\/article-pdf\/113\/4\/258\/33015652\/hcz278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T03:23:37Z","timestamp":1695353017000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/113\/4\/258\/5610088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,10,30]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcz278","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2019,10,30]]}}}